CDKN2B loss may be present in up to 8% of different types of cancer including glioblastoma, pancreatic, and lung adenocarcinoma.37,38 In urinary tract tumors, CDKN2B loss varies by histology and tumor site, being more frequent in urothelial cancer (up to 30%) and in SCC (up to 39%).39 From the point of view of new therapeutic options for PSCC, it is important to mention that CDKN2B loss in patients with non-small cell lung cancer is associated with worse efficacy and survival with ICI alone treatment, but not with ICI plus chemotherapy treatment.40 Here, CDKN2B is linked to non-small cell lung carcinoma.